bempikibart
Generic: ADX-914·Code: ADX-914
bempikibart: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Q32 Bio Inc. (QTTB) | Phase 2 |
Clinical Trials (1)
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Frequently asked questions
Who is developing bempikibart?
bempikibart is being developed by Q32 Bio Inc..
How many clinical trials involve bempikibart?
BioSniper tracks 1 clinical trial involving bempikibart.
Get deeper analysis on bempikibart
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis